Literature DB >> 16604564

Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.

Christopher I Li1, Kathleen E Malone, Babette S Saltzman, Janet R Daling.   

Abstract

BACKGROUND: Incidence rates of ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) have been rising, but little is known about which patients will develop invasive breast cancer or what types of tumors these patients may develop.
METHODS: By using Surveillance, Epidemiology and End Results (SEER) data, the authors evaluated how types of invasive breast cancers diagnosed among 37,692 DCIS and 4490 LCIS patients differed and how clinical characteristics influenced subsequent breast cancer risk.
RESULTS: Among DCIS patients, incidence rates of ipsilateral and contralateral invasive breast cancer were 5.4/1000 person-years and 4.5/1000 person-years, respectively; and among LCIS patients, incidence rates were 7.3/1000 person-years and 5.2/1000 person-years, respectively. LCIS patients were 5.3-fold more likely than DCIS patients to develop invasive lobular carcinomas. Women whose DCIS had comedo histologic features or was poorly differentiated had 1.4-fold and 2.0-fold elevations in ipsilateral invasive breast cancer risk. Furthermore, among DCIS patients, 20-49 year-olds and black women and Hispanic white women had 1.6, 2.7, and 2.3-fold elevated risks of Stage III/IV breast cancer compared with 50-59 year-olds and non-Hispanic whites, respectively.
CONCLUSIONS: Screening young DCIS patients more frequently and improving the follow-up care of blacks and Hispanic whites with DCIS may reduce their risk of advanced-stage breast cancer. In addition, LCIS may be a precursor rather than just an ambiguous risk factor for invasive breast cancer, and, therefore, localized treatment for LCIS may be warranted. Given that incidence rates of DCIS and LCIS have been rising, investigations of these tumors should be continued to better understand their etiology and appropriate clinical management. Copyright 2006 American Cancer Society

Entities:  

Mesh:

Year:  2006        PMID: 16604564     DOI: 10.1002/cncr.21864

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

1.  Use of annual mammography among older women with ductal carcinoma in situ.

Authors:  Phyllis Brawarsky; Bridget A Neville; Garrett M Fitzmaurice; Michael J Hassett; Jennifer S Haas
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

2.  Racial disparities in risk of second breast tumors after ductal carcinoma in situ.

Authors:  Ying Liu; Graham A Colditz; Sarah Gehlert; Melody Goodman
Journal:  Breast Cancer Res Treat       Date:  2014-09-27       Impact factor: 4.872

3.  Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast.

Authors:  Adele A Bailes; Henry M Kuerer; Sara A Lari; Lovell A Jones; Abenaa M Brewster
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

4.  Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ.

Authors:  Matthew W Conklin; Ronald E Gangnon; Brian L Sprague; Lisa Van Gemert; John M Hampton; Kevin W Eliceiri; Jeremy S Bredfeldt; Yuming Liu; Nuntida Surachaicharn; Polly A Newcomb; Andreas Friedl; Patricia J Keely; Amy Trentham-Dietz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

5.  Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ.

Authors:  Brian L Sprague; Amy Trentham-Dietz; Hazel B Nichols; John M Hampton; Polly A Newcomb
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

6.  Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence.

Authors:  Agnieszka K Witkiewicz; Boris Freydin; Inna Chervoneva; Magdalena Potoczek; Wendy Rizzo; Hallgeir Rui; Jonathan R Brody; Gordon F Schwartz; Michael P Lisanti
Journal:  Cancer Biol Ther       Date:  2010-08-21       Impact factor: 4.742

7.  Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management.

Authors:  Meghan R Flanagan; Mara H Rendi; Kristine E Calhoun; Benjamin O Anderson; Sara H Javid
Journal:  Ann Surg Oncol       Date:  2015-04-17       Impact factor: 5.344

8.  Ductal carcinoma in situ in African American versus Caucasian American women: analysis of clinicopathologic features and outcome.

Authors:  Hind Nassar; Bashar Sharafaldeen; Kala Visvanathan; Daniel Visscher
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

9.  Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9.

Authors:  Dengfeng Cao; Kornelia Polyak; Marc K Halushka; Hind Nassar; Nina Kouprina; Christine Iacobuzio-Donahue; Xinyan Wu; Saraswati Sukumar; Jessica Hicks; Angelo De Marzo; Pedram Argani
Journal:  Breast Cancer Res       Date:  2008-10-27       Impact factor: 6.466

10.  Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting.

Authors:  Laurel A Habel; Ninah S Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Stuart J Schnitt; Laura C Collins; Ann M Geiger; Balaram Puligandla; Luana Acton; Charles P Quesenberry
Journal:  Breast Cancer Res       Date:  2009-11-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.